CGIX - Cancer Genetics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2690
+0.0015 (+0.56%)
As of 9:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2675
Open0.2780
Bid0.2605 x 1100
Ask0.2650 x 1800
Day's Range0.2601 - 0.2780
52 Week Range0.2000 - 1.9300
Volume96,169
Avg. Volume2,284,341
Market Cap15.138M
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-0.9430
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Could The Cancer Genetics, Inc. (NASDAQ:CGIX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.last month

    Could The Cancer Genetics, Inc. (NASDAQ:CGIX) Ownership Structure Tell Us Something Useful?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • GlobeNewswire2 months ago

    Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced public offering of 15,217,392 shares of its common stock ("Common Stock") at a public offering price of $0.23 per share.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 28) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • GlobeNewswire2 months ago

    Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public offering of 15,217,392 shares of its common stock, offered at a price to the public of $0.23 per share, for gross proceeds of approximately $3.5 million, before deducting placement agent fees and other offering expenses payable by Cancer Genetics. The offering is expected to close on or about January 31, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • GlobeNewswire2 months ago

    Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.  The offering is being conducted as a “best efforts” offering and the placement agent is not obligated to purchase any securities. Cancer Genetics intends to use the net proceeds from this offering to pay any amounts we are required to pay to our lenders, and if any proceeds remain available, to pay certain costs previously incurred by us in connection with our strategic initiatives and to fund working capital and other general corporate purposes.

  • Benzinga2 months ago

    Insider Buys Of The Week: Cancer Genetics, Dish Network, Valvoline

    Another CEO and fellow insiders took advantage of an offering of common shares. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. A DISH Network Corp (NYSE: DISH) executive vice president purchased added another 25,000 shares of this pay-TV provider early last week.

  • GlobeNewswire2 months ago

    Cancer Genetics Issues Letter to Shareholders

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders from its Chief Executive Officer, Jay Roberts. Happy New Year – we are pleased to provide an update on our activities and strategic development.  We believe that 2018 was an important time for re-assessing our corporate direction, consolidating our company operations and focusing our capabilities in our biopharma business to execute our restructuring, while focusing on revenue growth and accelerating our path to profitability.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • GlobeNewswire2 months ago

    Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $0.225 per share. Cancer Genetics also granted the underwriter a 45-day option to purchase up to an additional 2,000,000 shares of its common stock at the public offering price of $0.225 per share, less underwriting discounts and commissions. Cancer Genetics expects to receive aggregate gross proceeds of approximately $3.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.

  • GlobeNewswire2 months ago

    Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of William Finger as the Company’s Executive Vice President, Precision Medicine and Biopharma Solutions, effective immediately. Mr. Finger will be responsible for developing and overseeing Cancer Genetics’ Precision Medicine and Biopharma and Clinical Trial business unit.

  • GlobeNewswire3 months ago

    Cancer Genetics Terminates Proposed Merger with NovellusDx

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it has terminated the previously-announced merger agreement with NovellusDx, effective immediately. As a result of the termination of the merger agreement, the Company will pursue alternative strategic and financial transactions with the goal of enhancing shareholder value.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / Biotech stocks Adial Pharmaceuticals and Cancer Genetics were exploding in Thursday’s session. Adial moved higher on news that the company is considering expanding AD04 to treat opioid use disorder. Shares of Cancer Genetics had no news to explain its dramatic share price jump.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks4 months ago

    Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates

    Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Cancer Genetics: 3Q Earnings Snapshot

    On a per-share basis, the Rutherford, New Jersey-based company said it had a loss of 31 cents. Losses, adjusted for restructuring costs and costs related to mergers and acquisitions, came to 23 cents per ...

  • GlobeNewswire4 months ago

    Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates

    RUTHERFORD, N.J., Nov. 19, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular.

  • GlobeNewswire4 months ago

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing Cancer Genetics to pursue other opportunities. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability.

  • Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know
    Zacks5 months ago

    Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

    Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire6 months ago

    Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (CGIX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.